Companies

Jubilant Life pegs FY2012 capex at Rs 500 cr

PTI New Delhi | Updated on October 17, 2011 Published on October 17, 2011

Jubilant Life Sciences plans to invest Rs 500 crore on capital expenditure activities in the current financial year as it looks to mop up an additional Rs 1,200 crore in revenue.

“In FY2012, our overall capex plan is at Rs 500 crore, which is likely to generate revenues of more than Rs 1,200 crore at current market prices and full capacity utilisation,” Jubilant Life Sciences said in its annual report for 2010-11.

When contacted, the company declined to make available the exact investment made till date in the ongoing fiscal.

The company’s consolidated net sales for the year ended March 31, 2011, stood at Rs 3,433.4 crore.

Various projects on which the company plans to invest in the current fiscal include a new advance intermediate plant in the special economic zone (SEZ) at Bharuch in Gujarat.

The company also plans to expand the capacity of its life science chemicals plant in the Bharuch SEZ during FY’12.

Further, the company expects to commission its Symtet (a key ingredient for making insecticides and pesticides) plant at Bharuch in the current financial year.

The proposed expansions are likely to generate revenue of more than Rs 1,200 crore at full capacity utilisation, the report said.

The company is looking to launch 55 new products, including 26 new launches in solid dosage form and 19 active pharmaceutical ingredients (API) in the current fiscal, it said.

The products would primarily be used in central nervous system, anti-infectives and anti-allergic therapeutic areas, it said.

Published on October 17, 2011
This article is closed for comments.
Please Email the Editor